Evidence map›Paper›PMID 32967500›Full record

Trial reportThe Journal of international medical research2020

Shujun Yang, Tong Gao, Zhonghua Zheng, Binbin Lai, Lixia Sheng, Zhijuan Xu, Xiao Yan, Jiaping Wang, Shiwei Duan, Guifang Ouyang

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of international medical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 0 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Shujun YangDepartment of Hematology, Ningbo First Hospital, Ningbo, Zhejiang, China.
Tong GaoMedical Genetics Center, School of Medicine, Ningbo University, Ningbo, Zhejiang, China.
Zhonghua ZhengMedical Genetics Center, School of Medicine, Ningbo University, Ningbo, Zhejiang, China.
Binbin LaiDepartment of Hematology, Ningbo First Hospital, Ningbo, Zhejiang, China.
Lixia ShengDepartment of Hematology, Ningbo First Hospital, Ningbo, Zhejiang, China.
Zhijuan XuDepartment of Hematology, Ningbo First Hospital, Ningbo, Zhejiang, China.
Xiao YanDepartment of Hematology, Ningbo First Hospital, Ningbo, Zhejiang, China.
Jiaping WangDepartment of Hematology, Ningbo First Hospital, Ningbo, Zhejiang, China.
Shiwei DuanMedical Genetics Center, School of Medicine, Ningbo University, Ningbo, Zhejiang, China.
Guifang OuyangDepartment of Hematology, Ningbo First Hospital, Ningbo, Zhejiang, China.ORCID https://orcid.org/0000-0002-3411-3666
Ningbo First Hospital · CNNingbo University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of this prospective randomized controlled clinical trial was to explore the relationship between

methodsThere were 82 low-risk MDS patients who were randomly divided into the following two groups: androl, thalidomide, and PND capsule (ATP group, n = 41); or androl and thalidomide (AT group, n = 41). Hemoglobin and neutrophil and platelet counts and changes in

resultsThe plasma hemoglobin level increased in both groups after treatment. However, the platelet count increased only in the ATP group. Patients in the ATP group had a better platelet response than the AT group, and

conclusionPND can improve hematological parameters and decrease the

Indexed as

DNA MethylationMyelodysplastic SyndromesChinaFemaleGlutathione PeroxidaseHumansMaleSaponinsGlutathione PeroxidaseGPX3 protein, humanpai-neng-daSaponinsDNA methylationGPX3hematological responseLow-risk myelodysplastic syndromePai-Neng-Daplatelet

Identifiers

PMID32967500
PMCPMC7520939
OpenAlexW3088538875

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.